Miriplatin

Product NameMiriplatin
CAS141977-79-9
MFC34H66N2O4Pt
MW762
EINECS
MOL File141977-79-9.mol

Chemical Properties

storage temp.	Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
solubility	DMF : < 1 mg/mL (insoluble)
form	Solid
color	White to off-white

Usage And Synthesis

Uses

Miplatin is a platinum-based anticancer drug developed by Japan's Sumitomo Pharmaceutical Co., Ltd. It is used in the treatment of liver cancer, malignant lymphoma, non-small cell lung cancer, small cell lung cancer and superficial bladder cancer.

Biological Activity

Miriplatin (SM-11355) is a derivative of cisplatin containing myristate as a carrier ligand. It is a novel lipophilic platinum complex for the treatment of hepatocellular carcinoma.

in vitro

Miriplatin (SM-11355) suspended in LPD (miriplatin/LPD, 100 μg/mL) inhibits the growth of AH109A cells, forms platinum-DNA adducts, and induces apoptosis.

< b>

in vivo

Miriplatin (SM-11355) (0.02-0.4 mg/20 μL) in lipiodol reduces tumor growth rates in a dose dependent manner in rats bearing AH109A tumor cells. Miriplatin/LPD (400 μg/head) significantly reduces tumor growth rates the growth of tumor in rats bearing AH109A cells.